McKesson Corp stock (US58155Q1031): shares hold near record territory after solid fiscal Q4 results

McKesson Corp shares remain close to recent highs after the US healthcare distributor reported higher profit for its fiscal fourth quarter ended 03/31/2025 and detailed segment trends in pharmaceuticals and medical-surgical distribution.

McKesson Corp shares continue to trade near elevated levels on the New York Stock Exchange after the US healthcare distributor recently reported higher profit for its fiscal fourth quarter and full year ended 03/31/2025, underscoring steady demand in its core pharmaceutical distribution and healthcare services businesses.

The stock traded at around USD 650 on 06/04/2026 on the NYSE, according to data from Reuters as of 06/04/2026, keeping McKesson Corp close to its historical highs and reflecting the company’s position as a major component of the US healthcare supply chain.

McKesson Corp, headquartered in Irving, Texas, is listed in the United States with its primary listing on the NYSE under the ticker MCK, and the company is part of the S&P 500 healthcare sector, giving it broad visibility among US institutional and retail investors.

On Tradegate in Germany, McKesson Corp recently changed hands at about 651.20 EUR on 06/04/2026 according to FinanzNachrichten, providing German investors with an additional way to access the US healthcare distributor through a euro-denominated listing.

McKesson Corp reported its fiscal fourth-quarter and full-year 2025 results on 05/07/2025, stating that adjusted earnings per diluted share from continuing operations for the quarter were USD 11.69, compared with USD 7.19 in the prior-year period, according to the company’s press release published on 05/07/2025.

In the same fiscal Q4 2025 release dated 05/07/2025, McKesson Corp said that total revenues for the quarter reached approximately USD 76.36 billion, compared with about USD 68.9 billion in the fiscal fourth quarter a year earlier, highlighting growth in US pharmaceutical distribution volumes and specialty drug utilization.

For the full fiscal year ended 03/31/2025, McKesson Corp reported revenues of roughly USD 294.7 billion and adjusted earnings per diluted share from continuing operations of about USD 29.70, according to the company’s 05/07/2025 earnings announcement, underlining its role as one of the largest distributors of pharmaceuticals and medical products in North America.

The fiscal Q4 2025 press release dated 05/07/2025 also indicated that McKesson Corp generated strong cash flows from operations during the year, supported by its large-scale distribution operations and working-capital management, while continuing to return capital to shareholders through dividends and share repurchases.

According to McKesson Corp’s investor presentation and FY 2025 earnings materials released on 05/07/2025, the US Pharmaceutical segment remained the largest contributor to revenue in the fiscal year, driven by growth in branded, specialty, and generic pharmaceutical distribution to retail pharmacies, hospitals, and other care settings across the United States.

McKesson Corp also highlighted in its 05/07/2025 fiscal Q4 and full-year communication that its Medical-Surgical Solutions segment benefited from continued demand from physician offices, ambulatory surgery centers, and post-acute care providers, supporting revenue growth and demonstrating the breadth of its US healthcare customer base.

In its FY 2025 results statement issued on 05/07/2025, McKesson Corp confirmed that it continued to pay a regular quarterly dividend on its common stock, with the annualized dividend over the preceding 12 months amounting to about USD 2.71 per share, implying a modest dividend yield relative to its share price and underlining its primary focus on reinvestment and buybacks.

For German investors tracking the stock in euro terms, FinanzNachrichten reported on 06/04/2026 that McKesson Corp’s shares on Tradegate were trading around 651.20 EUR, with a 12-month dividend sum of 2.71 EUR per share resulting in a dividend yield of about 0.42 percent based on that euro share price level.

As of: 04.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: MCK
• Sector/industry: Healthcare distribution and services
• Headquarters/country: Irving, United States
• Core markets: United States pharmaceutical and medical product distribution, selected international operations
• Key revenue drivers: US pharmaceutical distribution, specialty drug distribution, medical-surgical supplies and healthcare technology solutions
• Home exchange/listing venue: NYSE (MCK)
• Trading currency: USD

McKesson Corp: core business model

McKesson Corp operates as a large-scale distributor of pharmaceuticals and medical products and as a provider of related healthcare services, generating most of its revenue by supplying drugs, specialty therapies, and medical-surgical items as well as supporting technology solutions to pharmacies, hospitals, and other care providers in North America.

Industry trends and competitive position

McKesson Corp competes within the US healthcare distribution and services industry, which is characterized by a small number of very large distributors that handle the majority of pharmaceutical and medical product flows from manufacturers to care providers in the United States.

Industry research from IQVIA and other healthcare data providers has pointed out in recent years that specialty pharmaceuticals and biologics are accounting for a growing share of drug spending in the United States, driving demand for sophisticated distribution capabilities and specialty logistics services, areas where McKesson Corp, alongside peers such as AmerisourceBergen (now Cencora) and Cardinal Health, is focused on expanding its offerings and infrastructure.

According to sector commentary in recent healthcare distribution analyses published through 2024 and early 2025, the consolidation of pharmacy customers and ongoing pressure on reimbursement continue to shape the competitive landscape, encouraging players like McKesson Corp to seek efficiency gains, negotiate scale-based purchasing agreements with manufacturers, and invest in technology and data solutions to help providers manage inventory and patient-care workflows.

McKesson Corp’s emphasis on specialty distribution, oncology networks, and pharmacy services aligns with broader industry trends in the US healthcare system, where payers, providers, and manufacturers are seeking to manage complex therapies more effectively and to improve patient adherence, particularly in chronic and high-cost disease areas that rely heavily on advanced pharmaceuticals.

At the same time, regulatory changes and policy debates around drug pricing in the United States form an important backdrop for McKesson Corp’s competitive position, as potential shifts in reimbursement structures and discount mechanisms could affect margins throughout the pharmaceutical supply chain, requiring distributors to carefully manage contracts and operating costs.

In this environment, McKesson Corp’s scale in US pharmaceutical distribution, combined with its diversification into medical-surgical supplies and healthcare technology solutions, positions it as a central intermediary between drug manufacturers and a broad set of healthcare providers, though competition from other large distributors and from vertically integrated healthcare groups remains a key factor.

Conclusion

McKesson Corp’s share price holding near record territory on the NYSE comes against the backdrop of higher profit and revenue reported for fiscal Q4 2025 and the full year ended 03/31/2025, confirming the importance of its US pharmaceutical and medical-surgical distribution operations.

The broader US healthcare distribution industry, in which McKesson Corp competes with major peers such as Cencora and Cardinal Health, continues to be shaped by growth in specialty pharmaceuticals, customer consolidation, and evolving reimbursement frameworks, all of which influence margins and capital-allocation decisions for large intermediaries.

How McKesson Corp manages these sector dynamics, including the balance between investment, shareholder returns, and regulatory developments around drug pricing, will be key drivers for the company’s longer-term earnings trajectory and for investors assessing the stock within the US healthcare and S&P 500 universe.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.